Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Asmanex/Foradil combo development

Executive Summary

Schering-Plough and Novartis will develop Asmanex/Foradil combination product to treat asthma and chronic obstructive pulmonary disorder, the companies announced April 10. Schering's pending NDA for Asmanex (mometasone) was submitted Nov. 30, 1998. In November 2002, Schering acquired U.S. marketing rights to Novartis' Foradil (formoterol) (1"The Pink Sheet" Nov. 4, 2002, p. 22)...

You may also be interested in...

Schering-Plough Puffs Up Asthma Line With Foradil From Novartis

Schering-Plough is plugging a hole in its asthma product line by in-licensing Novartis' Foradil

Stockwatch: Subdued Virtual J.P. Morgan Conference Prefaces Full-Year Earnings Season

Deals announced by Sanofi and Novartis at this year’s virtual J.P. Morgan Healthcare Conference and a smattering of full-year revenue preannouncements did not mark a bumper start to the year.

Government Report Outlines Costs, Savings Of Major Regs

The HHS was responsible for the most major regulations over the last few years of any agency, an OMB report shows.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts